AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference

Press Release

View printer-friendly version

<<  Back

AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference

CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and Citi's 5th Annual Biotech Day investment conference.

Data from AVEO's tivozanib clinical development program will be presented at the following medical meetings:

  • 9th International Kidney Cancer Symposium (IKCS), October 1-2, 2010 at the Swissôtel in Chicago.
  • 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

In addition, William Slichenmyer, M.D., Sc.M., chief medical officer of AVEO, is scheduled to be featured on the panel, "Hidden Gems in Hematology/Oncology: A Survey of What to Keep an Eye on," on Tuesday, October 5, 2010 at 3:00 p.m. EDT as part of Citi's 5th Annual Biotech Day investment conference at the Westin Waterfront Hotel in Boston.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.

SOURCE: AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc.
Investor Contact:
Monique Allaire, 617-299-5810
or
Pure Communications
Media Contact:
Caton Lovett, 910-232-7166